Published in BMJ on July 10, 2013
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol (2013) 4.00
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res (2010) 2.23
Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. J Pathol (2012) 2.07
Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf) (2005) 2.07
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol (2010) 2.01
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol (2007) 1.93
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat (2011) 1.90
Variation in incidence of breast, lung and cervical cancer and malignant melanoma of skin by socioeconomic group in England. BMC Cancer (2008) 1.89
Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol (2008) 1.89
Responses of Müller glia to retinal injury in adult zebrafish. Vision Res (2004) 1.85
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol (2008) 1.75
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Res (2010) 1.65
Second primary cancers in patients with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries. Cancer Causes Control (2007) 1.61
National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol (2003) 1.56
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab (2006) 1.54
Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42,103 individuals. Gut (2012) 1.52
The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Res Treat (2011) 1.47
Factors influencing the use of thoracic radiotherapy in lung cancer--an analysis of the 1995 Scottish lung cancer audit. Clin Oncol (R Coll Radiol) (2002) 1.47
Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab (2011) 1.45
Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries. Int J Cancer (2008) 1.44
Improved treatment and survival for lung cancer patients in South-East Scotland. J Thorac Oncol (2008) 1.43
Risk of second cancer among women with breast cancer. Int J Cancer (2006) 1.41
Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. J Natl Cancer Inst (2007) 1.34
Clinical relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 cancers. J Clin Oncol (2010) 1.34
Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. Eur J Cancer (2007) 1.32
Clinicians' assessments of practice guidelines in oncology: the CAPGO survey. Int J Technol Assess Health Care (2004) 1.26
Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res (2010) 1.22
Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist (2011) 1.21
Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Endocr Relat Cancer (2006) 1.21
A study to evaluate nurse-led on-treatment review for patients undergoing radiotherapy for head and neck cancer. J Clin Nurs (2007) 1.21
Is the Scottish population living dangerously? Prevalence of multiple risk factors: the Scottish Health Survey 2003. BMC Public Health (2010) 1.20
Oropharyngeal cancer. Fastest increasing cancer in Scotland, especially in men. BMJ (2010) 1.20
Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomarkers Prev (2008) 1.18
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol (2005) 1.15
Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res (2007) 1.12
Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol (2007) 1.11
Associations between small intestine cancer and other primary cancers: an international population-based study. Int J Cancer (2006) 1.10
Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer (2007) 1.09
Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-up. Histopathology (2009) 1.06
Colorectal cancer survival in the Nordic countries and the United Kingdom: excess mortality risk analysis of 5 year relative period survival in the period 1999 to 2000. Int J Cancer (2007) 1.05
Rectal cancer survival in the Nordic countries and Scotland. Int J Cancer (2009) 1.04
In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat (2011) 1.02
Cellular pattern formation in the retina: retinal regeneration as a model system. Mol Vis (2002) 1.01
Impact of the UK colorectal cancer screening pilot studies on incidence, stage distribution and mortality trends. Cancer Epidemiol (2012) 1.00
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol Cancer Ther (2007) 0.99
Harmonization may be counterproductive--at least for parts of Europe where public health research operates effectively. Eur J Public Health (2011) 0.99
Targeted effects of retinoic acid signaling upon photoreceptor development in zebrafish. Dev Biol (2005) 0.99
Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol (2008) 0.99
Changing trends in incidence of lung cancer by histologic type in Scotland. Int J Cancer (2002) 0.98
Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer (2013) 0.97
Differential contextual responses of normal human breast epithelium to ionizing radiation in a mouse xenograft model. Cancer Res (2010) 0.96
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat (2006) 0.96
A pooled analysis of second primary pancreatic cancer. Am J Epidemiol (2006) 0.94
Does the 'Scottish effect' apply to all ethnic groups? All-cancer, lung, colorectal, breast and prostate cancer in the Scottish Health and Ethnicity Linkage Cohort Study. BMJ Open (2012) 0.93
Cellular correlates of proneural and Notch-delta gene expression in the regenerating zebrafish retina. Vis Neurosci (2007) 0.93
Current perspective - trastuzumab. Eur J Cancer (2008) 0.92
Legislation is needed to stop children using sunbeds. BMJ (2009) 0.92
Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance. Mol Endocrinol (2007) 0.91
Cohort profile: Scottish health and ethnicity linkage study of 4.65 million people exploring ethnic variations in disease in Scotland. Int J Epidemiol (2010) 0.91
Control of cellular pattern formation in the vertebrate inner retina by homotypic regulation of cell-fate decisions. J Neurosci (2005) 0.91
Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? No. BMJ (2011) 0.89
Socioeconomic inequalities in incidence of lung and upper aero-digestive tract cancer by age, tumour subtype and sex: a population-based study in Scotland (2000-2007). Cancer Epidemiol (2012) 0.89
Correcting population-based survival for DCOs - why a simple method works and when to avoid it. Eur J Cancer (2009) 0.89
Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis (2005) 0.88
Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer (2012) 0.88
The influence of deprivation and ethnicity on the incidence of esophageal cancer in England. Cancer Causes Control (2009) 0.88
Age-related cone abnormalities in zebrafish with genetic lesions in sonic hedgehog. Invest Ophthalmol Vis Sci (2008) 0.87
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer (2009) 0.87
Patients with prostate cancer are less likely to develop oesophageal adenocarcinoma: could androgens have a role in the aetiology of oesophageal adenocarcinoma? Cancer Causes Control (2009) 0.87
Reduced risk of oestrogen receptor positive breast cancer among peri- and post-menopausal women in Scotland following a striking decrease in use of hormone replacement therapy. Eur J Cancer (2010) 0.86
Photoreceptor differentiation during retinal development, growth, and regeneration in a metamorphic vertebrate. J Neurosci (2004) 0.86
Plasticity of photoreceptor-generating retinal progenitors revealed by prolonged retinoic acid exposure. BMC Dev Biol (2011) 0.86
Retinal ectopias and mechanically weakened basement membrane in a mouse model of muscle-eye-brain (MEB) disease congenital muscular dystrophy. Mol Vis (2010) 0.86
Health economics in drug development: efficient research to inform healthcare funding decisions. Eur J Cancer (2010) 0.85
Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence. Pharmacoeconomics (2011) 0.85
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol (2005) 0.85
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. Breast Cancer Res Treat (2013) 0.84
Cardiovascular disease and air pollution in Scotland: no association or insufficient data and study design? BMC Public Health (2012) 0.83
Layer 6 cortical neurons require Reelin-Dab1 signaling for cellular orientation, Golgi deployment, and directed neurite growth into the marginal zone. Neural Dev (2012) 0.83
Effects of induced systemic hypothyroidism upon the retina: regulation of thyroid hormone receptor alpha and photoreceptor production. Mol Vis (2006) 0.82
Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study. Breast Cancer Res Treat (2010) 0.82
Population-based estimates of the occurrence of multiple vs first primary basal cell carcinomas in 4 European regions. Arch Dermatol (2012) 0.81
Up-to-date estimates of breast cancer survival for the years 2000-2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer (2010) 0.81
Assessment of the effect of chemotherapy on ovarian function in women with breast cancer. J Clin Oncol (2007) 0.80
Advancing cancer drug discovery towards more agile development of targeted combination therapies. Future Med Chem (2012) 0.80
A qualitative investigation of the motivations, experiences and views of female sunbed users under the age of 18 in England. J Public Health (Oxf) (2013) 0.80
Impact of screening and risk factors for local recurrence and survival after conservative surgery and radiotherapy for early breast cancer: results from a large series with long-term follow-up. Int J Radiat Oncol Biol Phys (2011) 0.80
High constant incidence rates of second primary cancers of the head and neck: a pooled analysis of 13 cancer registries. Int J Cancer (2010) 0.79
Declining breast cancer incidence and decreased HRT use. Lancet (2009) 0.78
The risk of oesophageal cancer is not affected by a diagnosis of breast cancer. Eur J Cancer Prev (2010) 0.78
Associations between ocular melanoma and other primary cancers: an international population-based study. Int J Cancer (2007) 0.78